This review assessed the effectiveness of moxibustion as a treatment option for pain and concluded that there was limited evidence for its effectiveness in treating osteoarthritis of the knee, but most of the existing trials have a high risk of bias. The cautious conclusions and recommendation for more rigorous studies appear appropriate.
Study selection
Randomised clinical trials (RCTs) that tested moxibustion (direct or indirect) in patients with any type of pain where pain was a central symptom of their condition were eligible for inclusion. RCTs could be placebo-controlled, controlled against another treatment of documented effectiveness or compared with no treatment. Studies that compared moxibustion with other treatments of unproven effectiveness were excluded. It appeared that the primary outcome was reduction of pain.
All studies except one used indirect moxibustion. All included studies were conducted in China. Control group drug therapy included diclofenac sodium, magnesium sulfate and ribavirin. Regimen details for both moxibustion and drug therapies were reported. Participants in the included studies had osteoarthritis of the knee, scleroma or herpes zoster (shingles).
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
Two reviewers assessed study risk of bias using criteria for sequence generation, missing data, blinding (patient and assessor blinding assessed separately) and allocation concealment. Disagreements between reviewers were resolved by discussion.
Data extraction
Two reviewers independently extracted data required to calculate risk ratios (RRs) with 95% confidence intervals for response rates to moxibustion. Primary authors were contacted where there was insufficient information. It appeared that disagreements were resolved by discussion.
Methods of synthesis
Where appropriate, risk ratios with 95% CIs for response rates were pooled using what appeared to be a random-effects model. Heterogeneity was assessed using Χ 2 and I 2 tests. Studies not included in the meta-analysis were described narratively.
Results of the review
Four RCTs (n=375, range 60 to 135) were included in the review. All studies had unclear reporting of blinding and allocation concealment. All studies except one had unclear reporting of outcome measures. Only one study adequately described sequence generation. The reviewers reported that only one RCT reported sufficient details of dropouts and withdrawals.
